AML treatment advances now available to patients in the US; Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation detected with the LeukoStrat CDx FLT3 Mutation Assay tinyurl.com/ybfnspab

Last summer, MLDIP published on how @TeenageCancer services help young patients with #cancer in the UK. This week, children with leukaemia will have access to a new CAR-T cell therapy via the #NHS Cancer Drugs Fund. Fantastic news for young patients! tinyurl.com/yd2ot6op

AML is one of the most aggressive blood cancers, so it’s great news that AbbVie/Roche received FDA Accelerated Approval for VENCLEXTA® (venetoclax). Hopefully patients in the UK will also have access soon. news.abbvie.com/article_disp…

There’s a huge unmet need in follicular lymphoma so we’re excited to see Nordic Nanovector’s Betalutin granted Promising Innovative Medicine designation by the @MHRAgovuk #nordic tinyurl.com/ybv5jloc

Great news for people with chronic lymphocytic leukaemia as Venclyxto and MabThera combination gets approved. 👍 tinyurl.com/yb57slns #CLL #Roche #Abbvie

#WBCD #makeyourmark

May 28 is #WorldBloodCancerDay! Make your mark and share to show solidarity with blood cancer patients. #wbcd thndr.me/m4lqJZ

@MLDIP_Hayward making our mark for #WorldBloodCancerDay

A great read it is too! Thanks for writing for us @laura_coster! xitter.cf/laura_coster/status/78…